Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4

Research progress of tumor targeted drug delivery based on PD-1/PD-L1

(2022) Dongzhu Liu et al.   INTERNATIONAL JOURNAL OF PHARMACEUTICS

Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients

(2021) Yida Wang et al.   Annals of Translational Medicine

Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma

(2021) David Johnson et al.   ORAL ONCOLOGY

Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy

(2021) Oliver Klein et al.   CANCER CELL

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, Versus Chemotherapy in Patients With Recurrent/Metastatic Nasopharyngeal Cancer

(2021) Caroline Even et al.   CLINICAL CANCER RESEARCH

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

(2021) Hao Zhang et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

The Landscape of Immunotherapy in Advanced NSCLC: Driving Beyond PD-1/PD-L1 Inhibitors (CTLA-4, LAG3, IDO, OX40, TIGIT, Vaccines)

(2021) Andrea De Giglio et al.   Current Oncology Reports

Targeting immune checkpoints: Building better therapeutic puzzle in pancreatic cancer combination therapy

(2020) Sina Abdkarimi et al.   EUROPEAN JOURNAL OF CANCER CARE

Hepatotoxicity from Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation

(2020) Thoetchai (Bee) Peeraphatdit et al.   HEPATOLOGY

A decade of immune-checkpoint inhibitors in cancer therapy

(2020) Caroline Robert   Nature Communications

Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin® Proteins

(2020) Emelie Foord et al.   Journal of Immunology Research

Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

(2020) Lin Shen et al.   Journal for ImmunoTherapy of Cancer

Synergistic Local Combination of Radiation and Anti-Programmed Death Ligand 1 Immunotherapy Using Radiation-Responsive Splintery Metallic Nanocarriers

(2020) Bongseo Choi et al.   ACS Nano

Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors

(2020) Kuo-Ching Mei et al.   ACS Nano

Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment

(2020) Yuxiao Song et al.   Frontiers in Immunology

Electric Pulse Responsive Magnetic Nanoclusters Loaded with Indoleamine 2,3-Dioxygenase Inhibitor for Synergistic Immuno-Ablation Cancer Therapy

(2020) Bo Yu et al.   ACS Applied Materials & Interfaces

Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies

(2020) Elisabeth Pérez-Ruiz et al.   DRUG RESISTANCE UPDATES

Impact of Radiotherapy Concurrent with Anti-PD-1 Therapy on the Lung Tissue of Tumor-Bearing Mice

(2019) Feng Wang et al.   RADIATION RESEARCH

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

(2019) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Toripalimab: First Global Approval

(2019) Susan J. Keam   DRUGS

Sintilimab: First Global Approval

(2019) Sheridan M. Hoy   DRUGS

Use of Immune Checkpoint Inhibitors in Mesothelioma

(2019) Patrick M. Forde et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade

(2019) Fangyuan Zhou et al.   ADVANCED MATERIALS

Dual Functional Immunostimulatory Polymeric Prodrug Carrier with Pendent Indoximod for Enhanced Cancer Immunochemotherapy

(2019) Zhuoya Wan et al.   Acta Biomaterialia

Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment

(2019) Adela Wu et al.   JOURNAL OF NEURO-ONCOLOGY

Immunogenic cell death in cancer therapy: Present and emerging inducers

(2019) Jingyi Zhou et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Combination of CTLA-4 and PD-1 blockers for treatment of cancer

(2019) Anand Rotte   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Immunostimulatory nanomedicines synergize with checkpoint blockade immunotherapy to eradicate colorectal tumors

(2019) Xiaopin Duan et al.   Nature Communications

Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer

(2019) Alessandro Leonetti et al.   DRUG RESISTANCE UPDATES

Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study

(2019) Yuqin Song et al.   LEUKEMIA

Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma

(2019) Saqib R. Ahmed et al.   Expert Review of Clinical Pharmacology

Janus Nanobullets Combine Photodynamic Therapy and Magnetic Hyperthermia to Potentiate Synergetic Anti‐Metastatic Immunotherapy

(2019) Zheng Wang et al.   Advanced Science

Photothermal-Chemotherapy Integrated Nanoparticles with Tumor Microenvironment Response Enhanced the Induction of Immunogenic Cell Death for Colorectal Cancer Efficient Treatment

(2019) Yayu Wen et al.   ACS Applied Materials & Interfaces

Co-delivery of Bee Venom Melittin and a Photosensitizer with an Organic–Inorganic Hybrid Nanocarrier for Photodynamic Therapy and Immunotherapy

(2019) Haojie Liu et al.   ACS Nano

Synergistic triple-combination therapy with hyaluronic acid-shelled PPy/CPT nanoparticles results in tumor regression and prevents tumor recurrence and metastasis in 4T1 breast cancer

(2019) Wei Sun et al.   BIOMATERIALS

Predominance of M2 macrophages in gliomas leads to the suppression of local and systemic immunity

(2019) Aurobind Vidyarthi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Photothermal-Activatable Fe3O4 Superparticle Nanodrug Carriers with PD-L1 Immune Checkpoint Blockade for Anti-metastatic Cancer Immunotherapy

(2018) Rui Ge et al.   ACS Applied Materials & Interfaces

Avelumab: a new standard for treating metastatic Merkel cell carcinoma

(2018) Mairead Baker et al.   Expert Review of Anticancer Therapy

Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors

(2018) Kristian M. Hargadon et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

(2018) Manish R Patel et al.   LANCET ONCOLOGY

Immuno-PET Imaging of 89Zr Labeled Anti-PD-L1 Domain Antibody

(2018) Dan Li et al.   MOLECULAR PHARMACEUTICS

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

(2018) Mark A. Socinski et al.   NEW ENGLAND JOURNAL OF MEDICINE

Elimination of established tumors with nanodisc-based combination chemoimmunotherapy

(2018) Rui Kuai et al.   Science Advances

Binary Cooperative Prodrug Nanoparticles Improve Immunotherapy by Synergistically Modulating Immune Tumor Microenvironment

(2018) Bing Feng et al.   ADVANCED MATERIALS

A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity

(2018) Prabhakaran Kumar et al.   JOURNAL OF AUTOIMMUNITY

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

(2018) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

(2018) Leora Horn et al.   NEW ENGLAND JOURNAL OF MEDICINE

Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway

(2018) Jianqin Lu et al.   ACS Nano

Nivolumab for the treatment of hepatocellular carcinoma

(2018) Fabian Finkelmeier et al.   Expert Review of Anticancer Therapy

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma

(2018) Stefania Oliva et al.   Frontiers in Immunology

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

(2017) Andrea B. Apolo et al.   JOURNAL OF CLINICAL ONCOLOGY

Lymphoma Immunochemotherapy: Targeted Delivery of Doxorubicin via a Dual Functional Nanocarrier

(2017) Qianyu Zhai et al.   MOLECULAR PHARMACEUTICS

Interference-like patterns of static magnetic fields imprinted into polymer/nanoparticle composites

(2017) Zhijie Yang et al.   Nature Communications

Product review on the Anti-PD-L1 antibody atezolizumab

(2017) Neil J. Shah et al.   Human Vaccines & Immunotherapeutics

Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma

(2017) Thomas Powles et al.   JAMA Oncology

Pembrolizumab and nivolumab: PD-1 inhibitors for advanced melanoma

(2016) Igor N. Ivashko et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer

(2016) Brant A. Inman et al.   CLINICAL CANCER RESEARCH

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma

(2016) Hong Zheng et al.   CLINICAL CANCER RESEARCH

Rationale for anti-CD137 cancer immunotherapy

(2016) Amani Makkouk et al.   EUROPEAN JOURNAL OF CANCER

Photodynamic Therapy Mediated by Nontoxic Core–Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer

(2016) Xiaopin Duan et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

192TiP: NEPTUNE: A global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy versus standard of care (SoC) platinum-based chemotherapy in the first-line treatment of patients (pts) with advanced or metastatic NSCLC

(2016) T. Mok et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

(2016) Scott J Antonia et al.   LANCET ONCOLOGY

Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor

(2016) Rong Deng et al.   mAbs

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy

(2016) Yichao Chen et al.   Nature Communications

Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy

(2016) Chunbai He et al.   Nature Communications

Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors

(2015) Anja Derer et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

(2015) Kim C. Ohaegbulam et al.   TRENDS IN MOLECULAR MEDICINE

New immunotherapies targeting the PD-1 pathway

(2015) Jordan M. Chinai et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody

(2015) R. Stewart et al.   Cancer Immunology Research

HDAC Inhibition Upregulates PD-1 Ligands in Melanoma and Augments Immunotherapy with PD-1 Blockade

(2015) D. M. Woods et al.   Cancer Immunology Research

Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

(2015) Kavitha Gowrishankar et al.   PLoS One

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

The role of the PD-L1:PD-1 pathway in squamous cell carcinoma of the head and neck

(2014) Dan P. Zandberg et al.   ORAL ONCOLOGY

At the Bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

(2013) Andrew M. Intlekofer et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Immunomodulating antibodies in the treatment of metastatic melanoma: The experience with anti-CTLA-4, anti-CD137, and anti-PD1

(2012) Ester Simeone et al.   Journal of Immunotoxicology

Re: Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer

(2012) Samir S. Taneja   JOURNAL OF UROLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune Checkpoint Proteins: A New Therapeutic Paradigm for Cancer—Preclinical Background: CTLA-4 and PD-1 Blockade

(2010) Jeffrey Weber   SEMINARS IN ONCOLOGY

CD28 and CTLA-4 coreceptor expression and signal transduction

(2009) Christopher E. Rudd et al.   IMMUNOLOGICAL REVIEWS